Clinical Trials Logo

Depressive Disorder clinical trials

View clinical trials related to Depressive Disorder.

Filter by:

NCT ID: NCT04517981 Enrolling by invitation - Prognosis Clinical Trials

Cohort Study on the Outcome and Influencing Factors of Perinatal Depression

Start date: September 1, 2019
Phase:
Study type: Observational

1. Research and follow-up of the course and outcome of high-risk pregnant women with perinatal depression in the third trimester; 2. Factors affecting the outcome of the disease; 3. Recurrence of PND in pregnancy again; 4. The influence of different intervention methods on the course of the disease.

NCT ID: NCT04509102 Enrolling by invitation - Clinical trials for Major Depressive Disorder

Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder

Stimulant-rTMS
Start date: September 27, 2021
Phase: Early Phase 1
Study type: Interventional

This study analyzes the affects or Adderall extended-release (XR) in Subjects receiving brain stimulation therapy for the treatment of Major Depressive Disorder. Subjects will be assigned by chance to active or placebo group. Active group will be asked to take one 15 mg pill once daily of Adderall XR (amphetamine) and the Placebo group will be asked take an identical appearing tablet/capsule, one tablet by mouth daily. The placebo tablet has no active ingredients and has no affect on the body or mind. With the exception of the study drug, all other study activities between both groups will be identical. Subjects will use the assigned study drug two weeks before therapy and throughout the first 10 therapy treatments. A total of seven(7) visits will be required for screening, drug assignment, and completion of mood assessments. This study will enroll a total of 30 Subjects.

NCT ID: NCT04497350 Enrolling by invitation - Clinical trials for Major Depressive Disorder

Transcranial Magnetic Stimulation vs Theta Burst Stimulation in Major Depressive Disorder

Start date: January 6, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the differences in efficacy between transcranial magnetic stimulation (TMS) and intermittent theta burst stimulation (iTBS) treatment in subjects suffering from major depressive disorder.

NCT ID: NCT04469608 Enrolling by invitation - Clinical trials for Major Depressive Disorder

Establishing TCM Daycare Model and Teaching Mechanism of Depression Patients

Start date: May 11, 2020
Phase: N/A
Study type: Interventional

The teaching platform of the TCM daycare clinics for depression patients will provide a good clinical training environment for the trainees. They can learn how to take care of depression patients by the lectures and the clinical practice experiences in the daycare clinics. They can also learn a holistic approach, a patient-centered healthcare service. This teaching model will strengthen the clinical training of TCM and enhance the international competitiveness of TCM doctors.

NCT ID: NCT04250441 Enrolling by invitation - Depression Clinical Trials

The Use of Transcranial Focused Ultrasound for the Treatment of Depression and Anxiety

Start date: November 1, 2018
Phase: N/A
Study type: Interventional

The purpose of this open label study is to evaluate longer term tolerability and early efficacy of transcranial ultrasound in the treatment of patients with refractory depression and anxiety.

NCT ID: NCT04234776 Enrolling by invitation - Depressive Disorder Clinical Trials

Intramuscular Ketamine Versus Aripiprazole and Escitalopram in the Treatment of Resistant Depression

KETProject
Start date: April 3, 2018
Phase: Phase 4
Study type: Interventional

The treatment of resistant depression should be optimized aiming at complete remission of symptoms, a complex condition due to several factors. Approximately 1/3 of patients with depressive disorders do not even respond to available antidepressants. Consequently, new molecules with robust action, fast effects and sustained improvement are currently being researched worldwide. Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has emerged as a promising alternative due to its involvement in neurogenesis, synaptogenesis and consequent rapid improvement of depressive and suicidal symptoms with traditional intravenous (IV) use in sub dose (0.5 mg / kg). The therapeutic response of IV use has been short and requires monitoring in a hospital setting. There are no studies evaluating response to long-term ketamine use. Recent research has focused on identifying other routes of ketamine use such as intranasal and intramuscular (IM). The use of ketamine IM, despite the fact that there are few studies and small samples, can demonstrate efficacy in acute treatment and maintenance of depression, as well as low profile of side effects, greater accessibility potential, reduced costs and risks, patient comfort and possible expansion of resistant depression treatment capabilities in different settings.

NCT ID: NCT04209296 Enrolling by invitation - Clinical trials for Major Depressive Disorder

Chart Review of Patients Undergoing Ketamine Infusions

Start date: December 3, 2019
Phase:
Study type: Observational

The Canadian Rapid Treatment Center of Excellence (CRTCE) is a healthcare facility principally focused on providing best practices of intravenous ketamine treatment to adult patients suffering from mental health conditions. The center focuses specifically on treating individuals suffering from major depression disorder, bipolar disorder, post-traumatic stress disorder and obsessive compulsive disorder as their primary diagnosis. Herein, this retrospective analysis aims to look at past data in order to further develop our understanding of ketamine in the use of psychiatry.

NCT ID: NCT04166864 Enrolling by invitation - Clinical trials for Major Depressive Disorder

Spectral Correlation Coefficient-determine TMS for Depression

SCC-TMS
Start date: June 16, 2019
Phase: N/A
Study type: Interventional

This study will investigate the feasibility, safety, and tolerability of administering repetitive Transcranial magnetic stimulation(TMS) at frequencies other than standard 10 Hz. This study will enroll 10 subjects who will undergo one quantitative electroencephalograph, one TMS procedure to determine the appropriate frequency and intensity for treatment, weekly mood/symptom assessments, and up to 30 TMS treatments. Subjects will be asked to participate for up to 6 weeks.

NCT ID: NCT04040062 Enrolling by invitation - Clinical trials for Major Depressive Disorder

Spectral Correlation Coefficient-based TMS

Start date: June 25, 2019
Phase: N/A
Study type: Interventional

This study will analyze the feasibility, safety, and tolerability of administering repetitive Transcranial magnetic stimulation(TMS) at frequencies other than standard 10 Hz. This study will enroll 10 subjects who will undergo one quantitative electroencephalograph, one TMS procedure to determine the appropriate frequency and intensity for treatment, weekly mood/symptom assessments, and up to 30 TMS treatments. Subjects will be asked to participate for up to 6 weeks.

NCT ID: NCT03847688 Enrolling by invitation - Clinical trials for Depression, Unipolar

Machine Learning to Predict Clinical Response to TMS

LEARN
Start date: October 22, 2018
Phase:
Study type: Observational

Major Depressive Disorder (MDD) is a common and debilitating illness. It affects a person's family and personal relationships, work, education, and life. It changes sleeping and eating habits and significantly impairs patients' general health. The disorder affects Veterans more than the general population, both as an isolated illness and in conjunction with posttraumatic stress disorder (PTSD) and suicidality. Symptoms in a notable proportion of patients (~30%) do not respond to behavioral and pharmacological interventions, and new treatments are in great need. One such treatment, transcranial magnetic stimulation (TMS), has been cleared by Food and Drug Administration for treatment in MDD. TMS is effective in around 60% of patients with treatment-resistant MDD but is associated with significant financial and time burden. Further insights into the neurobiological effects of TMS and markers for functional recovery prediction and treatment progression are of great value. The goal of this proposal is to use human electrophysiology (electroencephalography, hereafter EEG, in particular) and machine learning to predict treatment response in candidates for TMS treatment and also study TMS's mechanism of action. Doing so has several benefits for patients, as prediction of treatment helps providers in screening out the patients for whom TMS is ineffective and understanding the mechanism allows us to refine and individualize the treatment. The investigators will recruit 35 patients with treatment-resistant MDD and record resting state EEG signal with a dense electrode array before and after a 6-week clinical course of TMS treatment. The investigators will use machine learning (Sparse regressions) to predict treatment outcome using functional connectivity (Coherence) maps derived from the EEG signal. The investigators also will use classifiers to track changes in functional connectivity through the course of treatment. Based on our preliminary data, the investigators hypothesize that weaker functional connectivity between prefrontal cortex (where the stimulation is delivered) and parietal/posterior midline sites predict better response to treatment and that TMS treatment will enhance these connections. The data collected here would be used as a seed and preliminary data for future federal (NIH and the VA) career development awards which will focus on the use of EEG to better understand brain function and neuromodulation treatments.